World Video | Defence | Foreign Affairs | Natural Events | Trade | NZ in World News | NZ National News Video | NZ Regional News | Search

 


Southeast Asia: Drug-resistant malaria spread

Drug-resistant malaria has spread to critical border regions of Southeast Asia

31 July 2014

Bangkok: Drug-resistant malaria parasites have spread to critical border regions of Southeast Asia, seriously threatening global malaria control and elimination programmes, according to a study published in the New England Journal of Medicine.

The study confirms that resistance to the world’s most effective antimalarial drug, artemisinin, is now widespread in Southeast Asia. This is not the first, or even the second time the malaria parasite has developed resistance to front line drugs, and each time resistance has emerged from the same corner of Asia on the Cambodia-Thailand border.

The study, which analysed blood samples from 1241 malaria patients in 10 countries across Asia and Africa, found that artemisinin resistance in Plasmodium falciparum - the most deadly form of malaria-causing parasite – is now firmly established in Western Cambodia, Thailand, Vietnam, Eastern Myanmar and Northern Cambodia. There are also signs of emerging resistance in Central Myanmar, Southern Laos and Northeastern Cambodia.

Reassuringly, there are no signs of resistance in the three African sites included in the study, located in Kenya, Nigeria and Democratic Republic of the Congo.

The study also suggests that extending the course of antimalarial treatment in areas with established resistance – for six days rather than the standard three days – could offer a temporary solution to this worsening problem.

“It may still be possible to prevent the spread of artemisinin resistant malaria parasites across Asia and then to Africa by eliminating them, but that window of opportunity is closing fast.Conventional malaria control approaches won’t be enough – we will need to take more radical action and make this a global public health priority, without delay," said Professor Nicholas White, senior author of the study and Chairman of the Welcome Trust-funded Mahidol Oxford Tropical Medicine Research Unit (MORU), Professor of Tropical Medicine at the University of Oxford, and Chair of the Worldwide Antimalarial Resistance Network.

The study was conducted by the Tracking Resistance to Artemisinin Collaboration (TRAC) which enrolled infected adults and children at 15 trial sites in 10 malaria-endemic countries between May 2011 and April 2013. The TRAC partners examined the different responses in malaria infected patients to artemisinin treatment. Patients received a six-day antimalarial treatment, three days of an artemisinin derivative and a three day course of artemesinin combination treatment (ACT). Patients’ blood was analysed to measure the ‘parasite clearance half-life’ or rate at which the parasites are cleared from a patient’s blood.

Results showed that the median parasite clearance half-life ranged from 1.8 hours in the Democratic Republic of the Congo to 7 hours at the Thailand-Cambodia border, where artemisinin resistance has been known aboutsince 2005. The proportion of patients with parasites in their blood 72 hours after treatment, a widely used test for artemisinin resistance, ranged from 0% in Kenya to 68% in Eastern Thailand. Malaria infections that were slow to clear were also strongly associated with a single point mutation in a P. falciparum gene called kelch 13, an important validation of the recently discovered genetic marker (k13) in the DNA of the malaria parasite.

Researchers also found that patients who had slow clearing infections were also more likely to have parasite stages which can infect mosquitoes. This suggests that artemisinin-resistant P. falciparum parasites have a transmission advantage over parasites that are not resistant, which drives their spread.

“Frontline ACTs are still very effective at curing the majority of patients. But we need to be vigilant as cure rates have fallen in areas where artemisinin resistance is established,” said Dr Elizabeth Ashley, lead scientist of the TRAC study and Clinical Researcher at the Mahidol Oxford Tropical Medicine Research Unit (MORU), University of Oxford. “Action is needed to prevent the spread of resistance from Myanmar into neighbouring Bangladesh and India.”

Dr Jeremy Farrar, Director of the Wellcome Trust says: “If resistance spreads out of Asia and into Africa much of the great progress in reducing deaths from malaria will be reversed. Our ability to respond to these rapidly emerging health problems depends on swift gathering of evidence, which can be quickly translated into public health and clinical interventions that are then implemented. Antimicrobial resistance is happening now. This is not just a threat for the future, it is today's reality.”

Currently over half of the world’spopulation are at risk of malaria infection. Although there has been a substantial reduction in the number of people falling ill and dying from malaria – with approximately 3.3 million deaths prevented since 2000 – it is estimated that more than 600,000 people still die from the disease each year, most of them children under five years of age living in Africa.1

While new antimalarial medicines are indevelopment, and another paper published in the New England Journal of Medicine has shown some promising trial results for a potential new antimalarial drug in development at Novartis, they are unlikely to be available for widespread distribution for several years.

“The artemisinin drugs are arguably the best antimalarials we have ever had. We need to conserve them in areas where they are still working well,” concluded Dr Ashley.

Publication details: Elizabeth A Ashley et al. Spread of Artemisinin Resistance in Plasmodium falciparum Malaria. Advanced online publication in New England Journal of Medicine. July 31 2014; 371:411-23. DOI: 10.1056/NEJMoa1314981.

Notes to editors

•From the late 1950s to the 1970s chloroquine resistant malaria parasites spread across Asia to Africa, resulting in a resurgence of malaria infections and millions of deaths. Chloroquine was replaced by sulphadoxine-pyrimethamine (SP), but resistance to SP also emerged in Western Cambodia and spread to Africa. SP was replaced by ACTs, and now we face the prospect of history repeating itself for a third time.

•Artemisinin is the most effective drug against malaria. Artemisinin derivatives, such as artesunate, have several advantages over other antimalarial drugs such as chloroquine and mefloquine: the artemisinin derivatives act more rapidly and they have fewer side-effects. Although artemisinin derivatives can be used on their own - as a monotherapy - fears about the possible development of resistance led to recommendations that they should only be used in conjunction with one or more other drugs - as artemisinin combination therapies (ACTs).

•ACTs are now recommended by the World Health Organization as the firstline treatment for uncomplicated falciparum malaria, and they have contributed substantially to the recent decline in malaria cases in most tropical endemic regions.

•Some of key drivers of resistance in the malaria parasites are counterfeit or substandard treatments, unregulated antimalarial drug use, using artemisinin without a partner antimalarial as part of a combination treatment, and the unusual genetic structure of malaria parasites in Western Cambodia.

•The presence of kelch 13 mutations was strongly associated with a delayed parasite clearance from the patient’s system during treatment, and thus has been confirmed as a reliable marker of resistance. This will facilitate surveillance efforts going forward.

•Patients with slower parasite clearance are more likely to transmit their drug resistant strain to others.

•Treatment failure rates with artesunate-mefloquine in Thailand and with DHA-piperaquine in Cambodia have now risen more than fivefold.

•1 Malaria burden estimates from the WHO World Malaria Report 2013.

Funding
The TRAC project was funded by the UK Department for International Development (DFID). Additional support was given by the Worldwide Antimalarial Resistance Network (WWARN), the Intramural Research Program of the National Institute of Allergy and Infectious Diseases (NIAID) at the National Institutes of Health (NIH), and the Bill & Melinda Gates Foundation. The study was coordinated by MORU, the Mahidol Oxford Research Programme funded by the Wellcome Trust.

ENDS

© Scoop Media

 
 
 
 
 
World Headlines

 

Palestinian Refugees From Syria Face Worsening Situation

Palestinian women at a UNRWA distribution centre in the Jaramana refugee camp, Damascus, Syria. Photo: UNRWA/Carole Alfarah More>>

ALSO:

Greece Risks Prolonged Social Crisis

Greece’s severe financial crisis has bred social unrest and intolerance of the nearly one million irregular migrants living in the country (October 2012). Photo: IRIN/Kristy Siegfried More>>

Madagascar: Warning Of ‘rapid’ Spread Of Plague In Capital

Ny Hantra Andriatsifasoa survived the bubonic plague after being infected in Madagascar in 2011. Photo: IRIN/Tiana Randriaharimalala More>>

New Bird Flu Strain In Europe Threatens Poultry Sector

24 November 2014 – The United Nations Food and Agriculture Organization ( FAO ) today warned that a new bird flu strain detected in Europe poses a significant threat to the poultry sector, especially in low-resourced countries situated along ... More>>

Mexico: Disappearances Reach Record Number This Year

The National Registry of Missing Persons acknowledges that from 2007 to date, there are 23,605 cases of disappeared persons; 40% have been reported during the current administration of President Enrique Peña Nieto. More>>

Ban To Take Up Fight Against Ebola With All UN Organisations

Street sellers at Waterside market in central Monrovia, where there has seen a huge drop in customers over the past months due to the onset of the Ebola Virus Disease. Photo: UNDP/Carly Learson (20 November 2014) More>>

ALSO:

Darfur: UN-Backed Event Promotes Role Of Women In Peace

Darfur: amid mass rape allegations, UN-backed event promotes role of women in peace processes More>>

Ebola Cases No Longer Rising In Guinea And Liberia

In Conakry, Guinea, a mobilizer teaches children about proper handwashing techniques, which help prevent the spread of diseases, including Ebola. Photo: UNICEF/Timothy La Rose More>>

ALSO:


Get More From Scoop

 
 
 
 
 
World
Search Scoop  
 
 
Powered by Vodafone
NZ independent news